Lupisit D 10mg/50mg Tablet is a combination oral antidiabetic medication containing Dapagliflozin 10mg and Sitagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. The synergistic action of these agents improves glycemic control without significant risk of hypoglycemia when used appropriately. Lupisit D is recommended as adjunctive therapy to diet and exercise in patients inadequately controlled on monotherapy or as initial combination therapy in specific cases. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment. Common adverse effects include urinary tract infections, nasopharyngitis, and gastrointestinal disturbances. Caution is advised in patients with a history of hypersensitivity, renal dysfunction, or volume depletion. Regular monitoring of renal function, glycemic parameters, and hydration status is essential during treatment. Lupisit D offers an effective option for optimizing glycemic control in type 2 diabetes, contributing to improved metabolic outcomes and reduced risk of diabetes-related complications.